These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

838 related articles for article (PubMed ID: 24462983)

  • 1. HLA-haploidentical T cell-depleted allogeneic hematopoietic stem cell transplantation in children with Fanconi anemia.
    Zecca M; Strocchio L; Pagliara D; Comoli P; Bertaina A; Giorgiani G; Perotti C; Corbella F; Brescia L; Locatelli F
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):571-6. PubMed ID: 24462983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study.
    Choi I; Yoon SR; Park SY; Kim H; Jung SJ; Jang YJ; Kang M; Yeom YI; Lee JL; Kim DY; Lee YS; Kang YA; Jeon M; Seol M; Lee JH; Lee JH; Kim HJ; Yun SC; Lee KH
    Biol Blood Marrow Transplant; 2014 May; 20(5):696-704. PubMed ID: 24525278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Saudi experience in fludarabine-based conditioning regimens in patients with Fanconi anemia undergoing stem cell transplantation: excellent outcome in recipients of matched related stem cells but not in recipients of unrelated cord blood stem cells.
    Ayas M; Al-Seraihi A; El-Solh H; Al-Ahmari A; Khairy A; Aldali A; Markiz S; Siddiqui K; Al-Jefri A
    Biol Blood Marrow Transplant; 2012 Apr; 18(4):627-32. PubMed ID: 21871862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Graft manipulation and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation from mismatched unrelated and mismatched/haploidentical related donors in pediatric leukemia patients.
    Gonzalez-Vicent M; Perez A; Abad L; Sevilla J; Ramirez M; Diaz MA
    J Pediatr Hematol Oncol; 2010 Apr; 32(3):e85-90. PubMed ID: 20216238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fludarabine-based cytoreductive regimen and T-cell-depleted grafts from alternative donors for the treatment of high-risk patients with Fanconi anaemia.
    Chaudhury S; Auerbach AD; Kernan NA; Small TN; Prockop SE; Scaradavou A; Heller G; Wolden S; O'Reilly RJ; Boulad F
    Br J Haematol; 2008 Mar; 140(6):644-55. PubMed ID: 18302713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study.
    Mehta PA; Davies SM; Leemhuis T; Myers K; Kernan NA; Prockop SE; Scaradavou A; O'Reilly RJ; Williams DA; Lehmann L; Guinan E; Margolis D; Baker KS; Lane A; Boulad F
    Blood; 2017 Apr; 129(16):2308-2315. PubMed ID: 28179273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD-34 selected hematopoetic stem cell transplantation from HLA identical family members for fanconi anemia.
    Balci YI; Akdemir Y; Gumruk F; Cetin M; Arpaci F; Uckan D
    Pediatr Blood Cancer; 2008 May; 50(5):1065-7. PubMed ID: 18000858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution.
    Law J; Cowan MJ; Dvorak CC; Musick L; Long-Boyle JR; Baxter-Lowe LA; Horn B
    Biol Blood Marrow Transplant; 2012 Nov; 18(11):1656-63. PubMed ID: 22609040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fludarabine-based reduced intensity conditioning for stem cell transplantation of Fanconi anemia patients from fully matched related and unrelated donors.
    Bitan M; Or R; Shapira MY; Aker M; Resnick IB; Ackerstein A; Samuel S; Elad S; Slavin S
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):712-8. PubMed ID: 16785060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful engraftment without radiation after fludarabine-based regimen in Fanconi anemia patients undergoing genotypically identical donor hematopoietic cell transplantation.
    Tan PL; Wagner JE; Auerbach AD; Defor TE; Slungaard A; Macmillan ML
    Pediatr Blood Cancer; 2006 May; 46(5):630-6. PubMed ID: 16078221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors affecting the outcome of related allogeneic hematopoietic cell transplantation in patients with Fanconi Anemia.
    Ayas M; Siddiqui K; Al-Jefri A; El-Solh H; Al-Ahmari A; Khairy A; Markiz S; Shahin H; Al-Musa A; Al-Seraihy A
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1599-603. PubMed ID: 24960628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
    Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
    Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-Center Experience of Unrelated and Haploidentical Stem Cell Transplantation with TCRαβ and CD19 Depletion in Children with Primary Immunodeficiency Syndromes.
    Balashov D; Shcherbina A; Maschan M; Trakhtman P; Skvortsova Y; Shelikhova L; Laberko A; Livshits A; Novichkova G; Maschan A
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1955-62. PubMed ID: 26187864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.
    Koreth J; Kim HT; Lange PB; Bindra B; Reynolds CG; Chammas MJ; Armand P; Cutler CS; Ho VT; Glotzbecker B; Nikiforow S; Ritz J; Blazar BR; Soiffer RJ; Antin JH; Alyea EP
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1907-13. PubMed ID: 26055298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful T-cell-depleted, related haploidentical peripheral blood stem cell transplantation in a patient with Fanconi anaemia using a fludarabine-based preparative regimen without radiation.
    Rossi G; Giorgiani G; Comoli P; Nobili B; Salvaneschi L; De Stefano P; Maccario R; Locatelli F
    Bone Marrow Transplant; 2003 Mar; 31(6):437-40. PubMed ID: 12665837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
    Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclophosphamide-based in vivo T-cell depletion for HLA-haploidentical transplantation in Fanconi anemia.
    Thakar MS; Bonfim C; Sandmaier BM; O'Donnell P; Ribeiro L; Gooley T; Deeg HJ; Flowers ME; Pasquini R; Storb R; Woolfrey AE; Kiem HP
    Pediatr Hematol Oncol; 2012 Sep; 29(6):568-78. PubMed ID: 22839094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasible outcomes of T cell-replete haploidentical stem cell transplantation with reduced-intensity conditioning in patients with myelodysplastic syndrome.
    Shin SH; Kim JH; Jeon YW; Yoon JH; Yahng SA; Lee SE; Choi YS; Kim DY; Lee JH; Lee S; Kim HJ; Min CK; Lee JW; Lee KH; Min WS; Kim YJ; Lee JH
    Biol Blood Marrow Transplant; 2015 Feb; 21(2):342-9. PubMed ID: 25459640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete donor T cell chimerism predicts lower relapse incidence after standard double umbilical cord blood reduced-intensity conditioning regimen allogeneic transplantation in adults.
    Peterlin P; Delaunay J; Guillaume T; Gastinne T; Mahé B; Dubruille V; Blin N; Le Bourgeois A; Brissot E; Lodé L; Le Gouill S; Moreau P; Mohty M; Chevallier P
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):180-4. PubMed ID: 25175796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unrelated donor allogeneic hematopoietic stem cell transplantation for patients with hemoglobinopathies using a reduced-intensity conditioning regimen and third-party mesenchymal stromal cells.
    Kharbanda S; Smith AR; Hutchinson SK; McKenna DH; Ball JB; Lamb LS; Agarwal R; Weinberg KI; Wagner JE
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):581-6. PubMed ID: 24370862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.